Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORPIO: Perioperative Toripalimab and FOLFOX in HER2-negative Gastroesophageal Adenocarcinoma
NCT05986227Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of toripalimab in gastroesophageal adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicity and Pathological Complete Response Rate at 0.5 year. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT05986227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986227.